SCHEMBL2673231

SCHEMBL2673231

Cn1c(=O)[nH]c(Cl)c(-c2ccccc2)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMP P19971 1/20 0.50
ADORA2B P29275 3/20 0.49
ADORA3 P0DMS8 2/20 0.49
ADORA2A P29274 2/20 0.48
HTT P42858 2/20 0.47
ADORA1 P30542 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 4/20 0.42
HPGD P15428 4/20 0.42
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP2C9 P11712 1/20 0.42
PGR P06401 1/20 0.40
NR3C1 P04150 1/20 0.40
DPP4 P27487 1/20 0.40
GAA P10253 2/20 0.39
MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8541305 0.81 ADORA2B (0.56) TYMPADORA2BADORA3ADORA2AHTT
SCHEMBL7834105 0.78 ALDH1A1 (0.55) TYMPHTTKMT2ALMNASMN1; SMN2
SCHEMBL7847301 0.75 TYMP (0.43) TYMPADORA2BADORA3ADORA2AHTT
SCHEMBL31320788 0.75 ADORA2B (0.40) ADORA2BADORA3ADORA2AADORA1KMT2A
SCHEMBL2672956 0.72 NR3C1 (0.59) TYMPADORA2BADORA3ADORA2AADORA1
SCHEMBL10838564 0.71 KDM4E (0.48) ADORA2BADORA3ADORA2AHTTADORA1
SCHEMBL11680284 0.71 KDM4E (0.46) TYMPADORA2BADORA3HTTADORA1
SCHEMBL2673303 0.71 NR3C1 (0.48) TYMPADORA2BADORA3ADORA2AADORA1
SCHEMBL6948080 0.69 MEN1 (0.40) ADORA2BADORA3ADORA2AADORA1KDM4C
SCHEMBL29935990 0.68 KDM4E (0.47) TYMPADORA2BADORA2AHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173664-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
EP-1778236-B1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS INC (US) 2010-07-14 EP disclosed
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2009-11-05 US disclosed
US-7576076-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2009-08-18 US disclosed
EP-1778236-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS Corcept Therapeutics, Inc. (US) 2007-05-02 EP disclosed
WO-2006014394-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2006-02-09 WO disclosed
US-20060025405-A1 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025405-A1 Modified pyrimidine glucocorticoid receptor modulators NR3C1, NR3C2, TYMS TYMP 4/4885ADORA2B 172/4885ADORA3 123/4885
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS NR3C1, NR3C2, TYMS TYMP 4/4885ADORA2B 172/4885ADORA3 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.